The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. —- End —-.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

DECEMBER 3, 2020

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. About Trimer-Tag © Technology. About COVID-19 S-Trimer Vaccine. S-Trimer is intended to be adjuvanted.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

NOVEMBER 15, 2020

With promising preliminary safety and immunogenicity results from the Phase 1 clinical study, Clover aims to quickly expand its current 2 x 2000L capacity of the Cytiva FlexFactory, which went into service in January 2020. . SHANGHAI , Nov.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

Roots Analysis

SEPTEMBER 13, 2023

These molecules can be conjugated with various modalities, such as haptens, enzymes, isotopes, fluorescent tags, carrier proteins, polymers, particle conjugates and photoreactive molecules. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Development 40

Development Antibody Protein Drug Delivery Systems 40

XTalks

AUGUST 17, 2020

So again, these metrics are showing a novel biologic going into man, demonstrating safety, demonstrating tolerability, demonstrating exposure, demonstrating lack of immunogenicity, which has been a big challenge with protein therapeutics,” says Dr. Suri. And that’s really encouraging for us.”. “So

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

NOVEMBER 13, 2023

Jeremy Fry, Dr, Director of Sales, ProImmune, on: ‘Mastering immunogenicity and biologics development’. These topics include: subcutaneous administration and immunogenicity risk- current understanding and future considerations including novel modalities; and challenges and outlook of mRNA delivery and formulation.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

These include: Samantha Bailey-Bucktrout, PhD, Senior Vice President, Akamis Bio, on: ‘Tumour specific immunogene therapy to deliver protein therapeutics to solid tumour microenvironments’. Jonathan Fisher, PhD, Group Leader, University College London, on: ‘Local secretion of immune active proteins for direct and bystander tumour killing’.

Engineer 52

Engineer Antibody Protein In-Vivo 52